RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > BIO Head Calls for New Position to be Formed at FDA to Boost Innovation

BIO Head Calls for New Position to be Formed at FDA to Boost Innovation

Posted 20 April 2012 | By Alexander Gaffney, RAC 

The head of the Biotechnology Industry Organization (BIO), the leading trade group for biotechnology and biopharmaceutical organizations in the US, called on the US Food and Drug Administration (FDA) to make room in its organizational structure for a Chief Innovation Office (CIO), reports The Boston Business Journal.

Speaking at the organization's annual meeting in Boston, BIO President and CEO James Greenwood said FDA has a duty to go beyond its mission to protect consumers from unsafe and ineffective products, reports The Boston Business Journal.

"People who die because a product is not approved quickly enough are just as dead as those who die because a product is not safe," Greenwood said. "It's not just the job of the FDA to protect us-it's also to promote innovation."

Greenwood said the CIO position could help bring products through FDA's review process faster by evaluating the agency's rates of rejection and studying that rate's effect on industry innovation, reports The Boston Business Journal.


Read more:

The Boston Business Journal - BIO chief Greenwood says FDA needs chief innovation officer

 

© 2022 Regulatory Affairs Professionals Society.